- Home
- DTSS vs BCDA Comparison
DTSS vs BCDA Comparison
Compare DTSS & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTSS
- BCDA
- Stock Information
- Founded
- DTSS 2014
- BCDA N/A
- Country
- DTSS China
- BCDA United States
- Employees
- DTSS N/A
- BCDA N/A
- Industry
- DTSS Computer Software: Prepackaged Software
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- DTSS Technology
- BCDA Health Care
- Exchange
- DTSS Nasdaq
- BCDA Nasdaq
- Market Cap
- DTSS 16.5M
- BCDA 10.1M
- IPO Year
- DTSS N/A
- BCDA N/A
- Fundamental
- Price
- DTSS $1.96
- BCDA $2.29
- Analyst Decision
- DTSS
- BCDA Strong Buy
- Analyst Count
- DTSS 0
- BCDA 1
- Target Price
- DTSS N/A
- BCDA $25.00
- AVG Volume (30 Days)
- DTSS 37.4K
- BCDA 245.1K
- Earning Date
- DTSS 05-14-2025
- BCDA 08-12-2025
- Dividend Yield
- DTSS N/A
- BCDA N/A
- EPS Growth
- DTSS N/A
- BCDA N/A
- EPS
- DTSS N/A
- BCDA N/A
- Revenue
- DTSS $56,255,129.00
- BCDA $3,000.00
- Revenue This Year
- DTSS N/A
- BCDA N/A
- Revenue Next Year
- DTSS N/A
- BCDA N/A
- P/E Ratio
- DTSS N/A
- BCDA N/A
- Revenue Growth
- DTSS 144.20
- BCDA N/A
- 52 Week Low
- DTSS $1.63
- BCDA $1.63
- 52 Week High
- DTSS $3.55
- BCDA $4.66
- Technical
- Relative Strength Index (RSI)
- DTSS 46.32
- BCDA 53.34
- Support Level
- DTSS $1.89
- BCDA $2.26
- Resistance Level
- DTSS $2.11
- BCDA $2.45
- Average True Range (ATR)
- DTSS 0.09
- BCDA 0.15
- MACD
- DTSS 0.01
- BCDA 0.03
- Stochastic Oscillator
- DTSS 55.50
- BCDA 68.00
About DTSS Datasea Inc.
Datasea Inc is a technology company. Its offers provides acoustic business services (focusing on high-tech acoustic technologies and applications such as ultrasound, infrasound, and Schumann resonance), 5G application services (5G AI multimodal digital business), and other products and services to various corporate and individual customers. The business activity of the group functions through China.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).